Prominent publications by Isabelle Poizot‐Martin

KOL Index score: 17320

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm were offered switch to ...

Also Ranks for: Week 96 |  disoproxil fumarate |  protease inhibitors |  emtricitabine tenofovir |  viral load
KOL Index score: 14608

BACKGROUND: Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1-infected subjects with genotypic evidence of RAL resistance.

METHODS: Subjects received DTG 50 mg once daily (cohort I) or 50 mg twice daily (cohort II) while continuing a failing regimen (without RAL) through day 10, after which the ...

Also Ranks for: Dolutegravir Dtg |  resistant hiv |  type 1 |  3ring humans |  ral resistance
KOL Index score: 13818

OBJECTIVE: To compare body composition, body fat distribution and insulin secretion in patients taking nucleoside reverse transcriptase inhibitor (NRTI) therapy.

DESIGN AND SETTING: Cross-sectional study in three French AIDS clinical centres.

PATIENTS: Forty-three HIV-infected patients on long-term NRTI therapy including stavudine (n = 27) or zidovudine (n = 16) and 15 therapy-naive HIV-infected patients (control group).

MAIN OUTCOME MEASURES: Fat wasting was assessed by physical ...

Also Ranks for: Fat Wasting |  stavudine zidovudine |  lipodystrophy patients |  body composition |  tissue adult
KOL Index score: 13815

AIMS: To date, no data exist assessing the impact of either methadone or buprenorphine on adherence to highly active antiretroviral therapy (HAART) in the long term. This study was conducted in order to evaluate whether receiving take-home methadone and buprenorphine may ensure better adherence to HAART in individuals infected with human immunodeficiency virus (HIV) through injection drug use (IDU).

DESIGN: Longitudinal data on adherence, opioid substitution treatment (OST) and patient ...

Also Ranks for: Buprenorphine Treatment |  haart adherence |  antiretroviral therapy |  highly active |  ongoing injection
KOL Index score: 12575

OBJECTIVE: High hepatitis C virus (HCV) treatment uptake combined with effective direct-acting antiviral-based regimens resulted in a dramatic decline of HCV infection in French people living with HIV (PLWH). We assessed the yearly incidence of new HCV infection in PLWH enrolled in the large French Dat'AIDS cohort from 2012 to 2016 with a specific focus on MSM.

METHODS: The incidence of new HCV infection was determined yearly in HCV-negative PLWH with serological follow-up during ...

Also Ranks for: Incidence Hcv Infection |  serological followup |  plwh msm |  hcv 2016 |  hepatitis virus
KOL Index score: 12221

BACKGROUND & AIMS: There is little data available on the use of new oral direct-acting antiviral (DAA) regimens to treat human immunodeficiency virus and hepatitis C virus (HIV/HCV) co-infected patients in real-life settings. Here, the efficacy and safety of all-oral DAA-based regimens in HIV/HCV-co-infected patients enrolled in the French nationwide ANRS CO13 HEPAVIH observational cohort are reported.

METHODS: HIV/HCV-co-infected patients enrolled in the ANRS CO13 HEPAVIH observational ...

Also Ranks for: Co13 Hepavih |  french anrs |  hiv hcv |  patients cirrhosis |  antiviral regimens
KOL Index score: 12184

BACKGROUND: Fat distribution abnormalities have been reported in patients treated with various antiretroviral drug regimens. The LIPOCO study is an ongoing observational study of unselected HIV-infected patients which aims to better characterize such disorders and their metabolic correlations.

METHODS: Cross-sectional analysis of data collected at baseline in the first 154 male patients included. Investigators divided patients into four predetermined clinical categories of fat ...

Also Ranks for: Fat Distribution |  computed tomography |  antiretroviral therapy |  insulin levels |  patients lipoatrophy
KOL Index score: 11187

OBJECTIVE: To determine the predictors of virological and clinical failure in patients receiving a protease inhibitor as part of triple therapy.

METHODS: From the French Hospital Database on HIV, 1402 protease inhibitor-naive patients starting a highly active antiretroviral therapy regimen with ritonavir, saquinavir-hard gel capsule (hgc) or indinavir between July 1996 and March 1997, and with measured HIV RNA at baseline and at 12 months, were studied for progression to a new ...

Also Ranks for: Virological Failure |  protease inhibitor |  triple therapy |  12 months |  clinical progression
KOL Index score: 11160

BACKGROUND: We assessed a once-daily combination to simplify therapy in patients infected with human immunodeficiency virus type 1 (HIV-1).

METHODS: A total of 355 adults with plasma HIV-1 RNA levels <400 copies/mL were randomly assigned to either switch to once-daily emtricitabine, didanosine, and efavirenz (n=178) or maintain their protease inhibitor (PI)-based regimens (n=177). The primary end point was sustained suppression of plasma HIV-1 RNA levels to <400 copies/mL.


Also Ranks for: Daily Emtricitabine |  based regimen |  simplification therapy |  viral suppression |  didanosine efavirenz
KOL Index score: 10992

BACKGROUND: In France, it is estimated that 24% of HIV-infected patients are also infected with HCV. Longitudinal studies addressing clinical and public health questions related to HIV-HCV co-infection (HIV-HCV clinical progression and its determinants including genetic dimension, patients' experience with these two diseases and their treatments) are limited. The ANRS CO 13 HEPAVIH cohort was set up to explore these critical questions.To describe the cohort aims and organization, ...

Also Ranks for: Hiv Hcv |  13 hepavih |  longitudinal studies |  infected patients |  prospective cohort
KOL Index score: 10722

AIMS: To evaluate the interindividual variability in the plasma concentrations of lopinavir in the context of routine monitoring with or without treatment with a non-nucleoside reverse transcriptase inhibitor and to assess the interaction between the coformulation of lopinavir/ritonavir and efavirenz or nevirapine.

METHODS: Plasma trough and peak concentrations (C(trough), C(max)) of lopinavir from 182 HIV-1-infected patients were analysed by high-performace liquid chromatography. Three ...

Also Ranks for: Reverse Transcriptase |  therapeutic drug monitoring |  lopinavir ritonavir |  plasma concentrations |  533 133
KOL Index score: 10614

AIMS: The protease inhibitor indinavir is characterized by an important interindividual pharmacokinetic variability, which results from the actions of the metabolizing enzymes cytochrome P450 (CYP) 3A and the multidrug efflux pump P-glycoprotein (P-gp), encoded by MDR1. Using a population pharmacokinetic approach, we investigated the effect of several MDR1 and CYP3A5 polymorphisms on the pharmacokinetic parameters of indinavir in HIV-infected patients.

METHODS: Twenty-eight patients ...

Also Ranks for: Genetic Polymorphisms |  indinavir ritonavir |  95 confidence interval |  cytochrome p450 |  binding cassette
KOL Index score: 10497

Multiple nucleoside resistance involves specific mutational patterns of the HIV-1 pol gene that are independent of the classic mutations conferring resistance to individual dideoxynucleosides. These include a cluster of five mutations in the reverse-transcriptase (RT) coding region (A62V, V75I, F77L, F116Y, and Q151M) generally referred to as multidrug resistance (MDR) mutations, and insertions of one or several amino acid residues between codons 67 and 70 of RT, a flexible region ...

Also Ranks for: Resistance Mutations |  reverse transcriptase |  beta3 beta4 |  extensively treated |  anti hiv
KOL Index score: 10422

Hepatitis E virus (HEV) is a newly-identified causative agent of acute and chronic hepatitis in severely immunocompromized patients. The present study sought to assess the prevalences of past, recent, on-going, and chronic HEV infections in patients infected with human immunodeficiency virus (HIV) in Marseille, South-eastern France, and to determine if they were correlated with the patients' immunological status or with cirrhosis. Anti-HEV IgG and IgM and HEV RNA testing were ...

Also Ranks for: Virus Infection |  patients infected |  viral sequence analysis |  hev rna |  cd4 count

Key People For Hiv Infection

Top KOLs in the world
Anthony * *****
hiv infection human immunodeficiency virus cd4 cells
Douglas * ********
antiretroviral therapy hiv infection human immunodeficiency virus
Andrew * *********
antiretroviral therapy viral load hiv infection
Steven * *****
antiretroviral therapy hiv infection cell activation
David * ******
antiretroviral therapy hiv infection viral load
Thomas * *****
chlamydia trachomatis hiv infection viral load

Isabelle Poizot‐Martin:Expert Impact

Concepts for whichIsabelle Poizot‐Martinhas direct influence:Hiv infection,  Infected patients,  Antiretroviral therapy,  Itpa deficiency,  Kaposi sarcoma,  Virological rebound,  Hiv infections,  Hcv patients.

Isabelle Poizot‐Martin:KOL impact

Concepts related to the work of other authors for whichfor which Isabelle Poizot‐Martin has influence:Antiretroviral therapy,  Hiv infection,  Human immunodeficiency virus,  Lung cancer,  Infected patients,  Protease inhibitors,  Viral load.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Aix-Marseille Univ, INSERM, IRD, SESSTIM, Sciences Économiques & Sociales de la Santé & Traitement de l’Information Médicale, ISSPAM, Marseille, France | APHM, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Inform